Sio Gene Therapies Inc. financial data

Industry
Pharmaceutical Preparations
Location
1501 Broadway, 12 Th Floor, New York, NY
Fiscal year end
March 31
Former names
Axovant Gene Therapies Ltd. (to 11/13/2020), Axovant Sciences Ltd. (to 4/18/2019), Roivant Neurosciences Ltd. (to 3/24/2015)
Latest financial report
10-Q - Q4 2022 - Feb 14, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 796 % -22.4%
Debt-to-equity 15.7 % +33.7%
Return On Equity -55.9 % +6.84%
Return On Assets -48.3 % +10%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 74M shares +0.37%
Common Stock, Shares, Outstanding 74M shares +0.38%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 74M shares +0.87%
Weighted Average Number of Shares Outstanding, Diluted 74M shares +0.87%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 20.4M USD -58.5%
General and Administrative Expense 9M USD -58.4%
Operating Income (Loss) -28.5M USD +53.8%
Income Tax Expense (Benefit) 283K USD +342%
Net Income (Loss) Attributable to Parent -28.8M USD +53.4%
Earnings Per Share, Basic -0.38 USD/shares +55.3%
Earnings Per Share, Diluted -0.38 USD/shares +55.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 46.1M USD -43.7%
Assets, Current 47.3M USD -47.5%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Assets 47.3M USD -49.3%
Accounts Payable, Current 201K USD -97%
Employee-related Liabilities, Current 572K USD -75.4%
Accrued Liabilities, Current 1.95M USD -74.9%
Liabilities, Current 2.15M USD -85.8%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 2.15M USD -87.4%
Retained Earnings (Accumulated Deficit) -878M USD -3.39%
Stockholders' Equity Attributable to Parent 45.1M USD -40.8%
Liabilities and Equity 47.3M USD -49.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.68M USD +31.4%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -277K USD -107%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 74M shares +0.38%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.96M USD -11.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 46.1M USD -44.5%
Deferred Tax Assets, Valuation Allowance 202M USD +9.95%
Deferred Tax Assets, Gross 203M USD +10.1%
Operating Lease, Liability 2.52M USD +102%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -28.8M USD +53.4%
Lessee, Operating Lease, Liability, to be Paid 2.93M USD +87.4%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 936K USD +244%
Lessee, Operating Lease, Liability, to be Paid, Year One 828K USD +153%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure -10.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 410K USD +28.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 799K USD +171%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 310K USD +2.31%
Depreciation, Depletion and Amortization 94K USD +54.1%
Interest Expense 27K USD -96.6%